Norges Bank
MRSN

Norges Bank’s Mersana Therapeutics MRSN Stock Holding History

Norges Bank’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-536
Closed -$357K – 2174
2020
Q4 		$357K Hold
536
– – ﹤0.01% 2093
2020
Q3 		$250K Buy
+536
New +$271K ﹤0.01% 2112
2018
Q2 		– Sell
-800
Closed -$315K – 2156
2018
Q1 		$315K Hold
800
– – ﹤0.01% 2103
2017
Q4 		$329K Hold
800
– – ﹤0.01% 2100
2017
Q3 		$346K Hold
800
– – ﹤0.01% 2108
2017
Q2 		$279K Buy
+800
New +$277K ﹤0.01% 2105

Other funds holding MRSN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Norges Bank's MRSN Position: Q1 2021 in Review

Norges Bank sold out of Mersana Therapeutics (MRSN) in Q1 2021, closing a stake of 536 shares — an estimated $357K sold.

Norges Bank first reported a position in MRSN in Q2 2017 and held it in 6 quarters. The position peaked at $357K in Q4 2020. 132 funds tracked by Wall St. Rank hold MRSN as of Q1 2021.

  • Norges Bank reported no remaining Mersana Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Norges Bank sold 536 Mersana Therapeutics shares in Q1 2021, an estimated $357K.
  • Norges Bank first reported a position in Mersana Therapeutics in Q2 2017 and held it in 6 quarters.
  • Norges Bank's Mersana Therapeutics position peaked at $357K in Q4 2020.
  • 132 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q1 2021.

Based on Norges Bank's 13F filing for Q1 2021, filed 7 May 2021.